Omeros Corporation (OMER): Price and Financial Metrics


Omeros Corporation (OMER): $2.70

0.17 (+6.72%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OMER to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

OMER POWR Grades

  • OMER scores best on the Quality dimension, with a Quality rank ahead of 80.64% of US stocks.
  • The strongest trend for OMER is in Stability, which has been heading up over the past 177 days.
  • OMER's current lowest rank is in the Growth metric (where it is better than 5.42% of US stocks).

OMER Stock Summary

  • With a price/earnings ratio of 0.8, OMEROS CORP P/E ratio is greater than that of about only 0.37% of stocks in our set with positive earnings.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -26.46 for OMEROS CORP; that's greater than it is for merely 1.01% of US stocks.
  • As for revenue growth, note that OMER's revenue has grown -188.26% over the past 12 months; that beats the revenue growth of just 0.22% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to OMEROS CORP are ATHX, NVAX, QURE, ENTA, and IDYA.
  • Visit OMER's SEC page to see the company's official filings. To visit the company's web site, go to www.omeros.com.

OMER Valuation Summary

  • In comparison to the median Healthcare stock, OMER's EV/EBIT ratio is 77.78% lower, now standing at 2.2.
  • Over the past 162 months, OMER's EV/EBIT ratio has gone up 12.2.

Below are key valuation metrics over time for OMER.

Stock Date P/S P/B P/E EV/EBIT
OMER 2023-01-20 -2.0 -3.5 0.8 2.2
OMER 2023-01-19 -2.2 -3.8 0.9 2.3
OMER 2023-01-18 -2.3 -3.9 0.9 2.3
OMER 2023-01-17 -2.3 -3.9 0.9 2.3
OMER 2023-01-13 -2.3 -3.9 0.9 2.3
OMER 2023-01-12 -2.1 -3.7 0.9 2.3

OMER Growth Metrics

    Its 5 year revenue growth rate is now at 144.46%.
  • Its 4 year net income to common stockholders growth rate is now at -45.48%.
  • Its 5 year net income to common stockholders growth rate is now at -45.48%.
OMER's revenue has moved down $101,499,000 over the prior 49 months.

The table below shows OMER's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 -79.889 -79.316 199.305
2022-06-30 -49.885 -76.538 194.058
2022-03-31 -21.062 -84.661 196.314
2021-12-31 0 -109.722 194.235
2021-09-30 90.52 -109.914 -123.659
2021-06-30 86.63 -121.194 -139.419

OMER's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OMER has a Quality Grade of B, ranking ahead of 81.69% of graded US stocks.
  • OMER's asset turnover comes in at 0.485 -- ranking 90th of 681 Pharmaceutical Products stocks.
  • HRTX, IRWD, and CHRS are the stocks whose asset turnover ratios are most correlated with OMER.

The table below shows OMER's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.485 0.987 -0.296
2021-03-31 0.446 0.987 -0.346
2020-12-31 0.495 0.988 -0.378
2020-09-30 0.699 0.987 -0.386
2020-06-30 0.962 0.989 -0.348
2020-03-31 1.041 0.991 -0.273

OMER Price Target

For more insight on analysts targets of OMER, see our OMER price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $37.43 Average Broker Recommendation 1.62 (Moderate Buy)

OMER Stock Price Chart Interactive Chart >

Price chart for OMER

OMER Price/Volume Stats

Current price $2.70 52-week high $7.75
Prev. close $2.53 52-week low $1.74
Day low $2.52 Volume 328,325
Day high $2.71 Avg. volume 373,656
50-day MA $2.40 Dividend yield N/A
200-day MA $3.44 Market Cap 169.37M

Omeros Corporation (OMER) Company Bio


Omeros Corporation is a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The company was founded in 1994 and is based in Seattle, Washington.


OMER Latest News Stream


Event/Time News Detail
Loading, please wait...

OMER Latest Social Stream


Loading social stream, please wait...

View Full OMER Social Stream

Latest OMER News From Around the Web

Below are the latest news stories about OMEROS CORP that investors may wish to consider to help them evaluate OMER as an investment opportunity.

Omeros Stock: Wild Market Gyrations But Deafening Silence (NASDAQ:OMER)

During its Q3 earnings call, Omeros reported on FDA''s initial response to its CRL appeal, setting the stage for progress toward approval. See why OMER is a Hold.

Seeking Alpha | December 27, 2022

CSCO, UAL and PAYX are among after hour mover

Gainers: Paychex (PAYX) +9%. Omeros Corporation (OMER) +7%

Seeking Alpha | December 23, 2022

Immuron, Omeros top healthcare gainers; Applied Molecular, NeuroBo lead losers'' pack

Immuron IMRN +43%. Omeros (OMER) +26%. Applied Molecular Transport AMTI -40%. NeuroBo Pharmaceuticals (NRBO) -24%.

Seeking Alpha | December 23, 2022

Omeros Corporation (NASDAQ: OMER) Has Fallen -168.38% From Its Highs, What Comes Next?

Omeros Corporation (NASDAQ:OMER)’s traded shares stood at 2.55 million during the latest session, with the company’s beta value hitting 1.10. At the last check today, the stock’s price was $2.91, to imply an increase of 14.06% or $0.36 in intraday trading. The OMER share’s 52-week high remains $7.81, putting it -168.38% down since that peak … Omeros Corporation (NASDAQ: OMER) Has Fallen -168.38% From Its Highs, What Comes Next? Read More »

Marketing Sentinel | December 23, 2022

Omeros Corporation (NASDAQ: OMER) Is Rated A Buy By Analysts.

In the last trading session, 1.1 million Omeros Corporation (NASDAQ:OMER) shares changed hands as the company’s beta touched 1.10. With the company’s per share price at $1.79 changed hands at -$0.17 or -8.67% during last session, the market valuation stood at $123.01M. OMER’s last price was a discount, traded about -343.02% off its 52-week high … Omeros Corporation (NASDAQ: OMER) Is Rated A Buy By Analysts. Read More »

Marketing Sentinel | December 19, 2022

Read More 'OMER' Stories Here

OMER Price Returns

1-mo 14.41%
3-mo -21.97%
6-mo -45.78%
1-year -49.63%
3-year -80.33%
5-year -84.14%
YTD 19.47%
2022 -64.85%
2021 -54.99%
2020 1.38%
2019 26.48%
2018 -42.67%

Continue Researching OMER

Want to see what other sources are saying about Omeros Corp's financials and stock price? Try the links below:

Omeros Corp (OMER) Stock Price | Nasdaq
Omeros Corp (OMER) Stock Quote, History and News - Yahoo Finance
Omeros Corp (OMER) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7469 seconds.